Bevacizumab in combination with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy for first-line and maintenance treatment of metastatic colorectal cancer-Reference-Cited by-同舟云学术

Bevacizumab in combination with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy for first-line and maintenance treatment of metastatic colorectal cancer

Published:2015-10-27 Issue:11 Volume:15 Page:1267-1281
ISSN:1473-7140
Container-title:Expert Review of Anticancer Therapy
language:en
Short-container-title:Expert Review of Anticancer Therapy

Author:

Grapsa Dimitra,Syrigos Konstantinos,Saif Muhammad Wasif

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Oncology

Link

http://www.tandfonline.com/doi/pdf/10.1586/14737140.2015.1102063

Reference96 articles.

1. Global cancer statistics, 2012

2. Annual report to the nation on the status of cancer, 1975-2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates

3. Recent trends in colorectal cancer mortality in Europe

4. Colorectal Cancer

5. Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer.

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Unraveling the immune landscape and therapeutic biomarker PMEPA1 for oxaliplatin resistance in colorectal cancer: A comprehensive approach;Biochemical Pharmacology;2024-04

2. Modified FOLFOX6 plus bevacizumab with and without nivolumab for first-line treatment of metastatic colorectal cancer: phase 2 results from the CheckMate 9X8 randomized clinical trial;Journal for ImmunoTherapy of Cancer;2024-03

3. Biosimilars in Colorectal Cancer;Biosimilars for Cancer Treatment;2024

4. Prediction of survival of preoperative colorectal patients: A new tool to assess the interaction of nutritional status and inflammation;Clinical Nutrition ESPEN;2023-08

5. Chalcones: An insight into their anticancer potential and action mechanism;SSRN Electronic Journal;2023